Exploring FDA-approved drugs based on specific tumor genes. Join a nationwide registry aiming to find new paths forward in precision medicine.
TAPUR: Testing the Use of FDA Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org.
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant.
TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Inclusion Criteria:
Review the criteria below to see if this study might be a good fit for you.
The prescreener preview is complete. You may now close the preview.
Explore the purpose and potential advantages of participating in the TAPUR Study for advanced stage cancer.
Access to FDA-approved targeted therapies contributed by collaborating pharmaceutical companies.
Explore treatment approaches based on your tumor's specific actionable genomic variant.
Help develop hypotheses for additional clinical trials by contributing to this vital registry.
Important details regarding participation in the TAPUR Study.
A clinical trial is a research study involving human volunteers to evaluate new medical approaches. The TAPUR Study is a non-randomized trial focused on describing the safety and efficacy of commercially available, FDA-approved targeted anticancer drugs. Patient safety is our highest priority, and you will be closely monitored by medical professionals throughout your participation.
The length of time you participate in the TAPUR Study depends on how your specific advanced cancer responds to the targeted therapy. You may continue to receive the study treatment as long as you are benefiting from it and not experiencing unacceptable side effects. Your study doctor will discuss the expected timeline based on your individual situation.
Because the TAPUR Study uses various FDA-approved targeted therapies, the specific risks and side effects depend on the exact medication prescribed for your tumor's genomic variant. Before you join, your doctor will provide a detailed document explaining the known risks associated with the specific drug you will receive.
Yes. Protecting your privacy is a fundamental requirement of this study. All your medical and personal information collected during the trial will be kept strictly confidential in accordance with HIPAA regulations and standard clinical research protocols. Your identity will not be revealed in any reports or publications resulting from the study.
Absolutely. Your participation in the TAPUR Study is entirely voluntary. You have the right to withdraw from the study at any time, for any reason, without any penalty or loss of benefits to which you are otherwise entitled. If you choose to leave, your doctor will discuss alternative treatment options with you.
You will receive the actual medication. The TAPUR Study is a non-randomized trial, meaning there is no placebo group. If you meet the eligibility criteria and your tumor harbors a specific genomic variant, you will be prescribed the corresponding targeted anticancer drug contributed by collaborating pharmaceutical companies.
After your participation concludes, you will continue to receive care from your regular oncologist. Results from the study are posted as they become available for individual cohorts at www.tapur.org/news. Additionally, all overall study results will be made available on clinicaltrials.gov at the end of the study to help inform future cancer treatments.